A three-university research team has successfully synthesized a nanozyme and used it to develop a paper-based disease substance detection sensor, which can detect six target substances simultaneously.Enzymes act as catalysts for various chemical reactions in a person’s body. Still, recently, reports
Pharma Essentia Korea said that the U.S. National Comprehensive Cancer Network (NCCN) guidelines have updated Besremi (Ingredient: ropeginterferon alfa-2b) as a recommended option for the treatment of polycythemia vera (PV).According to the company, Besremi is the only first-line treatment and next-
Korea United Pharm is seeking to expand the indication of Clanza CR (ingredient: aceclofenac), an incrementally modified drug (IMD) for relieving pain in various diseases.On Tuesday, the company said it began a clinical trial of Clanza CR to add an indication for “post-traumatic pain.”Clanza CR’s au
Yuhan Corp. said it canceled a licensing deal with Imnewrun Biosciences over brain disease treatment candidates.In a public filing on Tuesday, Yuhan said it terminated the agreement with Imnewrun signed on Feb. 19, 2020, intended for technology introduction and joint R&D of three brain disease drug
Sanofi’s nirsevimab, the first long-acting antibody that prevents respiratory syncytial virus (RSV) in infants just with a single administration, proved it could reduce the incidence of lower respiratory tract infection (LRTI) in phase 3 clinical trial. The results indicate that it could be in the f
Daewoong Pharmaceutical and Affyxell Therapeutics said they would cooperate with Seoul National University Hospital (SNUH) in developing regenerative medicine and advanced biopharmaceuticals.The three have signed a memorandum of understanding to establish a regenerative medical infrastructure and co
Bridge Biotherapeutics said that it signed an exclusive option-to-license agreement for Cellion BioMed’s ion channel modulator to develop a novel therapy for multiple fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).The substance, named BBT-301, is an innovative drug candidate that h
Novo Nordisk said it would enhance research and development of blood and rare endocrine diseases.On Monday, Novo Nordisk Korea announced renaming the existing Biopharm Business Unit as “Rare Disease Business Unit.”The new name signals Novo Nordisk’s global efforts to focus on R&D of rare and ultra-r
Daewoong Pharmaceutical’s U.S. partner Evolus said Monday that their botulinum toxin product Jeuveau (Nabota in Korea) showed immense sales growth last year, expecting the pace would continue this year.According to Evolus, the sales of Jeuveau in the U.S. reached $99.7 million last year, up 76 perce
Shinpoong Pharmaceutical and Ildong Pharmaceutical began their respective phase 3 clinical trials of oral Covid-19 treatments at community treatment centers (CTCs).On Monday, Korea National Enterprise for Clinical Trials (KONECT) said that CTCs, exclusively operated for clinical trials, started enro
Hanmi Pharmaceutical said that it has started marketing SynoJoynt, an osteoarthritis injection treatment, with Arthrex, a global medical device company, in the U.S.The treatment, also known as Hyalrheuma in Korea, is a high-molecular-weight hyaluronic acid product produced by Hanmi using its advance
The Ministry of Food and Drug Safety’s drug review panel passed BeiGene’s Brukinsa (ingredient: zanubrutinib), a treatment for mantle cell lymphoma (MCL), based on data from a phase 2 clinical trial because of the rarity of MCL.On Thursday, the MFDS released the minutes of the Central Pharmaceutical
Crystal Bioscience (CBS), a subsidiary of Crystal Genomics specializing in new technology project financing, said Friday it has become the first Korean company to list a special purpose acquisition company (SPAC) on the NASDAQ market.SPAC is a company established exclusively for acquiring unlisted c
AstraZeneca’s Koselugo (ingredient: selumetinib), the first rare disease treatment approved in Korea through an accelerated review due to the urgency to introduce the drug, failed to get health insurance benefits.The Health Insurance Review and Assessment Service (HIRA) held a Drug Reimbursement Eva
Novartis’ Lutathera (ingredient: Lutetium (177Lu) oxodotreotide), a treatment for neuroendocrine tumors, became reimbursable on Tuesday, reducing patients’ financial burdens significantly.According to the Ministry of Health and Welfare, Lutathera will be covered by health insurance for the third-lin
Genome and Company said it has entered a clinical collaboration agreement with MSD to develop biliary tract cancer treatment using a combination therapy of GEN-001 and Keytruda.Under the clinical trial collaboration and supply agreement, Genome and Company will conduct a phase 2 clinical trial to ev
Daewoong Pharmaceutical is seeking to expand the treatment scope of its botulinum toxin (BTX) Nabota (brand name in the U.S.: Jeuveau).On Monday, the Ministry of Food and Drug Safety said it approved Yonsei University Dental Hospital to conduct an investigator-initiated trial to confirm Nabota’s eff
Samil Pharmaceutical said it would open the first office in Vancouver, Canada, to enter the North American ophthalmology market.The opening ceremony will take place this month, the company said Wednesday.Samil’s office will start the registration work in May to release an eye-related medicine in Nor
GI Innovation said it has entered into a partnership with GI Cell and Yonsei University Health System (YUHS) to establish a cell therapy center for advanced biopharmaceuticals.Under the accord, GI Innovation and GI Cell will increase the production capability of advanced biopharmaceuticals with YUHS
Alvogen Korea's obesity treatment drug Qsymia (ingredient: phentermine/topiramate) posted more than 26 billion won ($21.5 million) in sales last year to become the only product to maintain growth among approved obesity drugs in Korea.According to IQVIA, a drug market research company, Qsymia recorde